Beta-cyclodextrin (β-CD) a cyclic oligosaccharide derived from starch through enzymatic conversion, is widely used as an additive in food, cosmetics, and pharmaceuticals due to its unique ability to encapsulate lipophilic compounds—improving stability, solubility, and bioavailability of active ingredients. As its application scope expands, concerns about its safety have gradually emerged among consumers and industry professionals. After rigorous evaluation by global regulatory bodies and decades of practical application data, β-CD is generally recognized as safe (GRAS) for oral and topical use within approved limits, though its safety varies significantly by administration route, dosage, and purity. Below is a structured, data-driven analysis of its safety profile, regulatory status, potential risks, and practical application guidelines.
Ⅰ. Global Regulatory Consensus: Clear Safety Standards
Major international and national regulatory authorities have established consistent safety thresholds for β-CD, confirming its low toxicity and safety under normal use scenarios through long-term toxicological studies:
1.JECFA (Joint FAO/WHO Expert Committee on Food Additives): Set an Acceptable Daily Intake (ADI) of 0–5 mg/kg body weight (bw) based on a 1-year chronic toxicity study in dogs, where the No-Observed-Effect Level (NOEL) was determined to be 470 mg/kg bw/day. A 100-fold safety factor was applied to ensure protection for all population groups, including children and pregnant women.
2. EFSA (European Food Safety Authority): Reaffirmed the 5 mg/kg bw/day ADI in its 2016 re-evaluation report, emphasizing that less than 1% of orally ingested Beta-Cyclodextrin β-CD is systemically absorbed. Most of it is metabolized by gut microbiota into glucose and maltose, which are then safely utilized by the body, with no accumulation in vital organs.
3.FDA (U.S. Food and Drug Administration): Classified β-CD as GRAS (Generally Recognized as Safe) for food use, with no upper limit specified for most applications such as baked goods, beverages, and confectionery, as its intake from normal diet is far below the ADI.
4. China (National Health Commission, NHC): Included β-CD in the National Food Safety Standard GB 2760, allowing its use in candies, beverages, processed meats, and dairy products. The purity requirement is set at ≥98% (per GB 1886.180), with strict limits on heavy metals (lead ≤1 mg/kg, arsenic ≤0.5 mg/kg) and microbial contamination to ensure raw material safety.
Ⅱ. Toxicity Profile: Low Acute & Chronic Risk
The safety of β-CD is primarily attributed to its poor systemic absorption and non-toxic metabolic pathway, which have been verified by numerous animal and human studies:
1.Acute toxicity: Beta-Cyclodextrin β-CD has extremely low acute toxicity. Oral toxicity studies in rats show a median lethal dose (LD₅₀) of 18.8 g/kg bw, which is far higher than the maximum possible daily intake from food, cosmetics, or pharmaceuticals—even for heavy consumers.
2.Chronic toxicity: Long-term animal studies (up to 2 years) have shown no evidence of carcinogenicity, mutagenicity, or reproductive harm when β-CD is administered at or below the ADI. High doses (>1,000 mg/kg bw/day) may cause reversible cecal enlargement in rats, a physiological adaptation to indigestible carbohydrates that has no significant relevance to human health, as human gut physiology differs from that of rats.
3.Topical/cosmetic use: In skin irritation and sensitization tests, Beta-Cyclodextrin was found to be non-irritating to intact or damaged skin and non-sensitizing to sensitive skin populations. It is widely approved in skincare, haircare, and oral care products to encapsulate fragrances, vitamins, and other actives, reducing irritation and improving ingredient stability without posing skin safety risks.
Ⅲ. Potential Risks & Side Effects (Dose & Route Dependent)
It is important to note that Beta-Cyclodextrin β-CD’s safety is conditional—risks only arise from misuse, excessive intake, or non-oral administration routes, which are avoidable with proper regulation:
1. Oral overconsumption: Exceeding the ADI (>5 mg/kg bw/day) may cause mild gastrointestinal discomfort, such as bloating, gas, or diarrhea, due to the osmotic effect of unmetabolized β-CD in the colon. These symptoms are reversible and subside once intake returns to normal. Rare allergic reactions have been reported in individuals with severe starch allergies, though such cases are extremely uncommon.
2. Parenteral (IV) use: Intravenous administration of Beta-Cyclodextrin poses high risks, as it can accumulate in the kidneys and form insoluble cholesterol complexes, leading to severe nephrotoxicity, renal failure, and even death. For this reason, β-CD is strictly not approved for parenteral use in any country or region.
3.Nutrient/drug interactions: β-CD may transiently bind to lipophilic vitamins (A, D, E, K) or certain lipophilic drugs in the gastrointestinal tract, potentially reducing their absorption. However, this effect is negligible at approved doses and fully reversible, with no long-term impact on nutrient status or drug efficacy.
Ⅳ. Safe Application Guidelines for Industry & Consumers
To ensure the safe use of Beta-Cyclodextrin across industries, manufacturers and consumers should adhere to the following best practices:
1.Food and cosmetics industry: Comply with the ADI (5 mg/kg bw/day) and local usage limits. Source β-CD with a purity of ≥98% from reputable suppliers, and request valid Certificates of Analysis (COA) and Material Safety Data Sheets (MSDS) to verify quality and safety.
2. Oral product manufacturers: Clearly label the content of β-CD on product packaging, and provide warnings for sensitive populations (such as children under 3 years old and pregnant women) to avoid excessive intake.
3. Cosmetic formulators: Beta-Cyclodextrin β-CD can be used in both leave-on and rinse-off products with no concentration restrictions (per global cosmetic regulations), but should be paired with compatible ingredients to avoid potential interactions.
– Strictly prohibit IV use: All formulations, including pharmaceuticals, must avoid intravenous administration of β-CD to prevent renal damage.
Ⅴ.Conclusion
In summary, beta-cyclodextrin is safe for its intended oral and topical use when manufacturers and consumers follow global regulatory standards, including the ADI and purity requirements. Its low systemic absorption, non-toxic metabolism, and decades of safe application data support its widespread use in food, cosmetics, and pharmaceuticals. The potential risks are limited to overconsumption or intravenous administration, both of which are easily avoidable with proper formulation, labeling, and compliance. For manufacturers, adhering to regulatory standards ensures product safety and market access; for consumers, normal dietary and cosmetic exposure to β-CD poses no meaningful health risk, making it a reliable and safe additive in daily products.
